In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (PRQR), with a price target of $25.00. The company’s shares closed last Monday at $6.07, close to its 52-week low of $5.62.
According to TipRanks.com, Nakae is ranked 0 out of 5 stars with an average return of -12.2% and a 31.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Emergent Biosolutions, and Arrowhead Research.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $24.00 average price target.
See today’s analyst top recommended stocks >>
Based on ProQR’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.09 million. In comparison, last year the company had a GAAP net loss of $6.93 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV operates as a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis.
